By Kristoff De Turck - reviewed by Aldwin Keppens
Last update: Jul 30, 2024
Pfizer reported impressive second-quarter results, surpassing revenue and adjusted earnings expectations, thanks to effective cost-cutting strategies, better-than-anticipated sales of its Covid antiviral pill, Paxlovid, and robust non-Covid product sales.
These results mark Pfizer’s first quarter of revenue growth since Q4 2022 and reflect its strategic efforts to stabilize business post-pandemic.
NYSE:PFE (7/30/2025, 11:21:06 AM)
24.1342
-0.17 (-0.68%)
Find more stocks in the Stock Screener